# Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

> **NCT00030537** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00030537
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030537, "Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00030537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*